С¶øÃÜ´ó½ÒÃØ | sdLDL-CÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄΣº¦Òò×Ó
Ðû²¼ÓÚ£º2021-06-18
ÎÄÕÂȪԴ£º[ÖÐÎÄ]±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎï
2ÐÍÌÇÄò²¡£¨T2DM£©»¼ÕßÓë΢Ѫ¹ÜºÍ´óѪ¹Ü²¢·¢Ö¢Ïà¹Ø£¬ÕâЩ²¢·¢Ö¢»áµ¼ÖÂÐÄÄÔѪ¹ÜÎÊÌâ[1-3]¡£ÓÐÑо¿Åú×¢£¬ÌÇÄò²¡»¼Õß±¬·¢¹Ú×´¶¯Âö¼²²¡£¨CAD£©ºÍÐļ¡¹£ËÀ£¨MI£©µÄΣº¦ÊÇ¿µ½¡È˵Ä2~3±¶£¬84%µÄ¡Ý65ËêÌÇÄò²¡»¼ÕßËÀÓÚÐÄÔಡºÍ×äÖÐ[4]¡£´ó´ó¶¼2ÐÍÌÇÄò²¡»¼ÕßѪ֬´úлÒì³££¬ÑªÖ¬Æ×ÌØÕ÷Ϊ֬ÖÊÈýÁªÕ÷£¬¼´¸ÊÓÍÈýõ¥£¨TG£©Éý¸ß£¬¸ßÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼£¨HDL-C£©Ï½µ¡¢µÍÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼£¨LDL-C£©Õý³£»òÇá¶ÈÉý¸ß£¬Ð¡¶øÃܵÍÃܶÈÖ¬ÂÑ°×£¨sdLDL£©¿ÅÁ£Ôö¶à¡£Ñо¿ÏÔʾ£¬sdLDL-CµÄˮƽÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄΣº¦Òò×Ó¡£
ƽ¶¥É½ÊÐÈËÃñÒ½ÔºÄÚÉø͸Óë´úл¿ÆµÄÌïÓµÈÈË[5]£¬ÕÐļÁË°üÀ¨352ÃûT2DM»¼Õߣ¨ÄÐ194Ãû£¬Å®158Ãû£¬Æ½¾ùÄêËê60.63Ë꣩ºÍ48Ãû¿µ½¡ÈË£¨ÄÐ34Ãû£¬Å®14Ãû£¬Æ½¾ùÄêËê45.38Ë꣩µÄÊÜÊÔÕß¡£Ì½ÌÖ¶à»ùÒò¶à̬ÐÔ¡¢LDL-CºÍsdLDL-CÔÚT2DMÖÎÁÆÖеÄÁÙ´²¼ÛÖµ¡£Ñо¿Ê±¼ä´Ó2018Äê5ÔÂÖÁ2020Äê1Ô¡£Ñо¿·¢Ã÷£¬sdLDL-CÖ÷Òª±£´æÓÚT2DM»¼ÕßÌåÄÚ£¬ÇÒT2DM»¼ÕßsdLDL-CµÄƽ¾ùˮƽ¸ßÓÚ¿µ½¡ÈË¡£ÖÎÁƺó£¬LDL-CºÍsdLDL-CµÄ±í´ï½ÏÖÎÁÆÇ°½µµÍÇÒ²î±ðÏÔÖø£¨p?0.001£©¡£Ð§¹ûÅú×¢£¬sdLDL-CÊÇT2DMµÄ¸ßΣÒòËØ¡£LDL-CºÍsdLDL-CÊÇT2DMÖÎÁƵÄÓÅÒì¼à²âÉúÎï±ê¼ÇÎï¡£

352ÀýÖÎÁÆÇ°µÄT2DM»¼Õß¼°48Àý¿µ½¡ÈËLDL-CºÍsdLDL-CµÄ±í´ï

10ÀýT2DM»¼Õߣ¨ÄÐ6Àý£¬Å®4Àý£©ÖÎÁÆÇ°ºó¼ì²âLDL-C£¬sdLDL-CµÄˮƽ¡£Êý×Ö1µ½10´ú±í²¡ÈË1µ½10
ÆëÆë¹þ¶ûҽѧԺÁ¥ÊôµÚÈýÒ½ÔºµÄÑîÐã¾²µÈ[6]£¬½«146ÀýT2DM»¼£¨ÆäÖÐÄÐ85Àý£¬Å®61Àý£»ÄêËê30¡«70Ë꣩Öд¿´âT2DM»¼Õß67ÀýΪ²¡Àý×é¢ñ£¬T2DM¼°²¢·¢Ö¢»¼Õß79ÀýΪ²¡Àý×é¢ò£»ÁíÑ¡ÔñͬÆÚ¿µ½¡Ìå¼ìÕß107Ãû×÷Ϊ±ÈÕÕ×é¡£Á½×é¾ù¾ÙÐÐsd LDL-C¡¢GLU¡¢TC¡¢TG¡¢LDL-C¡¢HDL-C¼ì²â¡£ÊÓ²ìT2DM¼°Æä²¢·¢Ö¢»¼ÕßѪÇåÖÐsdLDL-Cˮƽת±äÇéÐβ¢ÆÊÎöÆäÁÙ´²Ó¦ÓüÛÖµ¡£Ñо¿Ð§¹ûÅú×¢£¬sd LDL-CÔÚT2DM»¼ÕßÖÐÉý¸ßÏÔ×Å£¬sd LDL-CÓëTG¡¢TC¡¢LDL-C³ÊÕýÏà¹ØÓëHDL-C³Ê¸ºÏà¹Ø¡£ÊÓ²ìsd LDL-CµÄת±äÇéÐοÉÓÃÓÚÕ¹ÍûT2DM²¢·¢Ö¢²¡±ä±¬·¢Î£º¦¡£

¶«¾©´óѧ´óѧԺҽѧÑо¿ÔºÐÄѪ¹ÜÄÚ¿ÆAtsuko NakayamaµÈÈË[7]£¬¶Ô¸ßµ¨¹Ì´¼ÑªÖ¢ºÏ²¢ÌÇÄò²¡ÊÓÍøĤ²¡±ä»¼ÕßµÄËûÍ¡ÀàÒ©ÎïÇ¿»¯ÖÎÁÆÑо¿£¨n=5042£©¾ÙÐÐÁËÆÊÎö£¬¸ú×ÙÊÓ²ìÁË3.2¡À0.9Ä꣬ÆÀ¹ÀÁËÖ¬ÖÊÂþÑÜÓëÌÇÄò²¡ÊÓÍøĤ²¡±ä¼¤¹âÖÎÁÆÐèÇóÖ®¼äµÄÏà¹ØÐÔ¡£Ñо¿·¢Ã÷£¬sdLDL-CµÄˮƽÓëÔØÖ¬ÂÑ°×BµÄˮƽ³ÊÏÔÖøÕýÏà¹Ø£¨r=0.83£©£»sdLDL-CÊÇÕ¹ÍûCVÊÂÎñµÄÃô¸Ð±ê¼ÇÎp£¼0.01£©£»sdLDL-CÊÇÕ¹ÍûѪ֬»¼ÕßÊÇ·ñÐèÒª¼¤¹âÖÎÁƵÄÃô¸ÐÖ¸±ê£¨p=0.009£©¡£Ð§¹ûÅú×¢£¬sdLDL-CÊÇÕ¹Íû¸ßµ¨¹Ì´¼ÑªÖ¢ºÍÌÇÄò²¡ÊÓÍøĤ²¡±ä»¼ÕßÐÄѪ¹ÜÊÂÎñÒÔ¼°¼¤¹âÖÎÁÆÐèÇóµÄÃô¸Ð°Ðµã±ê¼ÇÎï¡£

sdLDL-Cˮƽ¶ÔÐÄѪ¹ÜÊÂÎñµÄÀÛ»ýΣÏձȺÍÌÇÄò²¡ÊÓÍøĤ²¡±ä¼¤¹âÖÎÁƵÄÐëÒªÐÔ

±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎïsd LDL-CÊÔ¼ÁºÐ
¹ýÑõ»¯Îïø·¨

1. Ê×¼Ò×¢²á¼°º£ÄÚÍƹ㣬¿Í»§ÈϿɶȸߣ»
2. ¹ýÑõ»¯Îïø·¨£¬Ó볬ËÙÀëÐÄ·¨ÓÐÓÅÒìµÄÏà¹ØÐÔ£¬¼ì²âЧ¹û׼ȷ¡¢¿ìËÙ£»
3. II bÐ͸ß֬Ѫ֢¡¢MetSµÈÌØÊâÑù±¾µÄ²âÖµ¸ü׼ȷ£»
4. ¿¹×ÌÈÅÐÔÄÜÓÅ£¬¼ì²â»ÆðãÑù±¾²»ÊÜÓ°Ï죻
5. »ñµÃ2016ÄêÖйúÌåÍâÕï¶ÏÊÔ¼ÁÁ¢Òì²úÆ·½±¡£

¡¾²Î¿¼ÎÄÏס¿
[1] Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and
risk of cause-specific death. N Engl J Med. 2011, 364(9), 829-41.
[2] American DA. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015, 33(2), 97-111.
[73] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823¨C8.
[4] Îâ¼Î,Íô¿¡¾ü.С¶øÃܵÍÃܶÈÖ¬ÂÑ°×¼ì²âÒªÁì¼°Ó¦ÓÃÏ£Íû[J].ÖлªÄ¥Á·Ò½Ñ§ÔÓÖ¾, 2017, 40(6), 417-419.
[5] Tian, Y., Wang, J., Liu, Y. et al. MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy. BMC Med Genomics 14, 83 (2021). https://doi.org/10.1186/s12920-021-00937-8.
[6] º«Ë¬, ÑîÐã¾², ÖìÔÂƽ, µÈ. sdLDL-CÔÚT2DM¼°Æä²¢·¢Ö¢»¼ÕßÖÐѪÇåˮƽת±ä¼°ÁÙ´²Ó¦ÓÃÆÊÎö[J]. ÆëÆë¹þ¶ûҽѧԺѧ±¨, 2019, 40(9), 1080-1081.
[7] Atsuko N, Hiroyuki M, Tatsuyuki S, et al. Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients. J Atheroscler Thromb. https://doi.org/10.5551/jat.62889
END
ÎÄÕÂȪԴ£º±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎï? |? Ôð±à£ºEcho ?|? У¶Ô£ºMiss Bio¡¢Dora